NEWTON, Mass.--(BUSINESS WIRE)--May 24, 2006--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel nanotechnology carbohydrate therapeutics, today announced it has entered into a research collaboration with Mount Sinai School of Medicine to evaluate the anti-fibrotic effects of some of the Company's novel, carbohydrate compounds. Mount Sinai has one of the world's largest, most productive and well-respected liver programs. Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.
